Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-01-03
2006-01-03
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S253130, C514S254010, C514S255010, C514S400000, C514S021800, C514S374000, C536S103000, C536S046000, C544S360000, C544S372000, C544S379000, C548S235000, C435S320100, C424S439000, C424S085100
Reexamination Certificate
active
06982256
ABSTRACT:
The invention relates to new formulations for improving the local tolerance of intravenously administered 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine or one of the pharmacologically acceptable acid addition salts thereof.
REFERENCES:
patent: 4727064 (1988-02-01), Pitha
patent: 5324750 (1994-06-01), Lincoln et al.
patent: 6323207 (2001-11-01), Eickmeier et al.
patent: 6407079 (2002-06-01), Muller et al.
patent: 198 43 489 (2000-03-01), None
patent: 0 149 197 (1997-01-01), None
patent: 1 029 872 (2000-08-01), None
patent: WO 96 19970 (1996-07-01), None
patent: WO 99 10008 (1999-03-01), None
patent: WO 00/04888 (2000-02-01), None
patent: WO 00 17176 (2000-03-01), None
patent: WO 02/064563 (2002-08-01), None
Loftsson, T. et al; “Pharmaceutical Applications of Cyclodextrins. 1. Drug Solubilization and Stabilization”; J. Pharm. Sci. 1996, 85, pp. 1017-1025.
Jäervinen, T. et al; “Sulfobutyl Ether beta-Cyclodextrin (SBE-beta-CD) in Eyedrops Improves the Tolerability of a Topically Applied Pilocarpine Prodrug in Rabbits”; J Ocul. Pharmacol. Ther., 1995, 11, pp. 95-106.
Arima, et al; “Enhanced Rectal Absorption and Reduced Local Irritation of the Anti-inflammatory Drug Ethyl 4-Biphenylylacetate in Rats by Complexation with Water-Soluble beta-Cyclodextrin Derivatives and Formulations as Oleaginous Suppository”; J. Pharm. Sci, 1992, 81, pp. 1119-1125.
Pitha, J. et al; “Hydroxypropyl-beta-cyclodextrin: preparation and characterization; effects on solubility of drugs”; Int J Pharmaceutics, 1986, 29, pp. 73-82.
Dass, C. R. et al; “Apolipoprotein A-1, Phospholipid Vesicles, and Cyclodextrins as Potential Anti-Atherosclerotic Drugs: Delivery, Pharmacokinetics, and Efficacy”; Drug Delivery, 2000, 7, pp. 161-182.
Gumina, R. J. et al; “Inhibition of the Na+/H+ Exchanger Confers Greater Cardioprotection Against 90 Minutes of Myocardial Ischemia Than Ischemic Preconditioning in Dogs”, Circulation, 1999, 100, pp. 2519-2526.
Nambu, N. et al; “Influence of Inclusion of Nonsteroidal Antiinflammatory Drugs with beta-Cyclodextrin on the Irritation to Stomach of Rats upon Oral Administration”; Chem. Pharm. Bull. 1978, 26, pp. 3609-3612.
Eickmeier, C. et al, “Benzoylguanidine Salt and Hydrates Thereof”; U.S. Appl. No. 10/057,597, filed Jan. 25, 2002.
Loftsson, T. et. al.; “Effects of 2-hydroxypropyl-Beta-cyclodexinin on the aqueous solubility of drugs and transdermal delivery of 17Beta-estradiol”; Acta Pharm. Nord. 1 (4) 1989; pp. 185-194.
Rajewski, R., et. al.; “Pharmaceutical Applications of Cyclodextrins. 2. In Vivo Drug Delivery”. Journal of Pharmaceutical Sciences, vol. 85; No. 11, Nov., 1996, pp. 1142-1169.
Kruss Bernd
Votteler Christine
Boehringer Ingelheim Pharma KG
Datlow Philip I.
Devlin Mary-Ellen
Khare Devesh
Morris Michael P.
LandOfFree
Tolerance of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tolerance of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tolerance of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3574214